Literature DB >> 9589244

Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin.

T Heise1, C Weyer, A Serwas, S Heinrichs, J Osinga, P Roach, J Woodworth, U Gudat, L Heinemann.   

Abstract

OBJECTIVE: To study the pharmacodynamic properties of three premixed formulations of the rapid-acting insulin analog insulin lispro and its protamine-retarded preparation, neutral protamine lispro (NPL) insulin. RESEARCH DESIGN AND METHODS: In this open, single-center, euglycemic glucose clamp study, 30 healthy volunteers (12 women, 18 men) aged 27 +/- 2 years (mean +/- SD), whose BMI was 23.0 +/- 2.3 kg/m2, received subcutaneous injections of 0.3 U/kg body wt of insulin mixture (high-mixture 75/25, mid-mixture 50/50, or low-mixture 25/75 insulin lispro/NPL insulin), insulin lispro, or NPL insulin on one of the five study days in randomized order. Glucose infusion rates were determined over a period of 24 h after administration.
RESULTS: Maximal metabolic activity decreased after subcutaneous injection of the mixtures with lower insulin lispro content; however, the time point of maximal and of early half-maximal metabolic activity was comparable among the three mixtures. Higher proportions of insulin lispro resulted in higher values for area under the curve within the first 360 min after injection and a more rapid decline to late half-maximal activity. Serum insulin concentrations showed a similar pattern.
CONCLUSIONS: This study shows that the pharmacodynamic and pharmacokinetic properties of insulin lispro are preserved in stable mixtures with NPL insulin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9589244     DOI: 10.2337/diacare.21.5.800

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  19 in total

Review 1.  Special considerations with insulin therapy in older adults with diabetes mellitus.

Authors:  Arshag D Mooradian
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

Review 2.  Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.

Authors:  Paris Roach; James R Woodworth
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Solution structure of an ultra-stable single-chain insulin analog connects protein dynamics to a novel mechanism of receptor binding.

Authors:  Michael D Glidden; Yanwu Yang; Nicholas A Smith; Nelson B Phillips; Kelley Carr; Nalinda P Wickramasinghe; Faramarz Ismail-Beigi; Michael C Lawrence; Brian J Smith; Michael A Weiss
Journal:  J Biol Chem       Date:  2017-11-07       Impact factor: 5.157

Review 4.  Glucose clamp algorithms and insulin time-action profiles.

Authors:  B Wayne Bequette
Journal:  J Diabetes Sci Technol       Date:  2009-09-01

Review 5.  A critical appraisal of the role of insulin analogues in the management of diabetes mellitus.

Authors:  Ralph Oiknine; Marla Bernbaum; Arshag D Mooradian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Insulin lispro: a review of its use in the management of diabetes mellitus.

Authors:  Dene Simpson; Paul L McCormack; Gillian M Keating; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Guidelines for optimal bolus calculator settings in adults.

Authors:  John Walsh; Ruth Roberts; Timothy Bailey
Journal:  J Diabetes Sci Technol       Date:  2011-01-01

Review 8.  Diabetes screening, diagnosis, and therapy in pediatric patients with type 2 diabetes.

Authors:  Helena W Rodbard
Journal:  Medscape J Med       Date:  2008-08-06

Review 9.  Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?

Authors:  David S H Bell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Postprandial blood glucose response to a standard test meal in insulin-requiring patients with diabetes treated with insulin lispro mix 50 or human insulin mix 50.

Authors:  Y Gao; G Li; Y Li; X Guo; G Yuan; Q Gong; L Yan; Y Zheng; J Zhang
Journal:  Int J Clin Pract       Date:  2008-07-24       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.